Moffitt Cancer Center· @MoffittNews · X·· 3 天前评分70
正文 · 原文
Can enfortumab vedotin plus pembrolizumab improve event-free survival in muscle-invasive bladder cancer?
Join Jonathan Chatzkel, MD, at #ESMO26 tomorrow, where he shares exploratory analyses from the KEYNOTE-B15/EV-304 trial. #MoffittESMO26
421 浏览 · 5 赞 · 3 转发 · 0 回复
会议摘要
4734O按 Proffered paper 1: Genitourinary tumour, renal and urothelial 对上
ctDNA analysis of the Phase 3 KEYNOTE-B15 trial: neoadjuvant and adjuvant (neoadj-adj) enfortumab vedotin (EV) + pembrolizumab (pembro) for participants (pts) with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin
https://esmocongress.esmo.orgNCT04700124NCT04700124按 - **标题 / Title：** Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304) 对上
- **标题 / Title：** Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)
https://esmocongress.esmo.org来源：Moffitt Cancer Center · x.com